Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
Yulin Zou, Zudong Meng Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan City, People’s Republic of ChinaCorrespondence: Zudong Meng Email zylmch1007@hbmu.edu.cnAbstract: The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combat...
Saved in:
Main Authors: | Zou Y (Author), Meng Z (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
by: Caleb Jeon, et al.
Published: (2017) -
Dual inhibition of IL-17A and IL-17F in psoriatic disease
by: Helena Iznardo, et al.
Published: (2021) -
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
by: Maria Concetta Fargnoli
Published: (2019) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017) -
Biologic anti-IL17 drugs in erythrodermic psoriasisCapsule Summary
by: Alessandro Falco, MD, et al.
Published: (2024)